Global Neurodegenerative Diseases Therapeutics Market (2018-2022) to Register a CAGR of Approx 8% - ResearchAndMarkets.com
Friday, 11 January 2019 02:06
Jan. 11, 2019 12:14 UTC

Global Neurodegenerative Diseases Therapeutics Market (2018-2022) to Register a CAGR of Approx 8% - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)-- The "Global Neurodegenerative Diseases Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The neurodegenerative diseases therapeutics market will register a CAGR of almost 8% by 2022.

Increase in aging population to drive growth in the market

The aging population has been increasing globally with declining fertility and increasing longevity. Medicine has prolonged the morbidity phase, which has, in turn increased the risk of developing neurological disorders such as Alzheimer's and Parkinson's disease.

Availability of highly sensitive diagnostic modalities

The development of advanced diagnostic modalities to identify disease manifestation at its earliest stages facilitates early treatment decisions, thereby easing disease burden. Neuroimaging is one of the methods for the early diagnosis of neurodegenerative diseases.

High failure rate of neurodegenerative drugs in clinical trials

There has been a continuous development of drugs for the treatment of neurodegenerative diseases. However, there is reportedly a high failure rate of neurodegenerative drugs in clinical trials.

Key Players

  • Allergan
  • Biogen
  • Novartis
  • Teva Pharmaceutical

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY INDICATION

  • Segmentation by indication
  • Comparison by indication
  • Multiple sclerosis - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Alzheimer's disease - Market size and forecast 2017-2022
  • Parkinson's disease - Market size and forecast 2017-2022
  • Huntington's disease - Market size and forecast 2017-2022
  • Market opportunity by indication

PART 09: MARKET SEGMENTATION BY DRUG CLASS

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

PART 14: MARKET TRENDS

PART 15: VENDOR LANDSCAPE

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Allergan
  • Biogen
  • Novartis
  • Teva Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/research/kk6qqx/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs


Source: Research and Markets




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter